ASCO QOPI
Quality Oncology Practice Initiative

ASCO CLINICAL AFFAIRS

QOPI® CERTIFICATION (QCP™) TRACK 2018 MEASURE SUMMARY

Module	Measure #	Measure
CORE	1	Pathology report confirming malignancy
CORE	2	Staging documented within one month of first office visit
CORE	6	Pain addressed appropriately (defect-free measure 3, 4a, and 5)
CORE	6a	Pain assessed on either of the two most recent office visits
CORE	9	Documented plan for chemotherapy, including doses, route, and time intervals
CORE	10	Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration
CORE	11	Chemotherapy intent discussion with patient documented
CORE	13oc4a	Documented plan for oral chemotherapy: Dose
CORE	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration)
CORE	16	Patient consent for chemotherapy (combined measure 14 or 15)
CORE	21aa	Smoking status/tobacco use documented in past year
CORE	24	Patient emotional well-being assessed by the second office visit
CORE	25	Action taken to address problems with emotional well-being by the second office visit
CORE	25b	Height, Weight, and BSA documented prior to curative chemotherapy
Symp/Tox	27	Corticosteroids and serotonin antagonist prescribed or administered with moderate/high emetic risk chemotherapy
Symp/Tox	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age
Breast	53	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer
Breast	54	Test for Her-2/neu overexpression or gene amplification
Breast	59	Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA(T1c) and IB - III ER or PR positive breast cancer
Colorectal	66	CEA within 4 months of curative resection for colorectal cancer
Colorectal	68	Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage III colon cancer
Colorectal	73	Colonoscopy before or within 6 months of curative colorectal resection or completion of primary adjuvant chemotherapy
Colorectal	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy
NSCLC	84	Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC

QOPI® CERTIFICATION (QCP™) TRACK 2018 MEASURE SUMMARY

Module	Measure #	Measure
NSCLC	88	Patients with Stage IV NSCLC with adenocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy
GYNONC	94	Platin or taxane administered within 42 days following cytoreduction to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer

